Kiora Pharmaceuticals (KPRX) CEO granted new equity awards

Rhea-AI Filing Summary

Strem Brian M. reported acquisition or exercise transactions in this Form 4 filing.

Kiora Pharmaceuticals President and CEO Brian M. Strem received new equity compensation awards. He was granted an option to buy 33,467 shares of Common Stock at $1.98 per share and 16,733 shares of restricted Common Stock, both at no cash cost to him.

The restricted stock vests in three equal installments on April 1, 2027, April 1, 2028, and April 1, 2029, subject to continued service. The option vests one-third on April 1, 2027, with the remaining balance vesting monthly over two years and expiring on April 1, 2036. Following these grants, he holds 62,598 Common shares directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Strem Brian M.

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	33,467	$0.00	--
Grant/Award	Common Stock	16,733	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 33,467 shares (Direct); Common Stock — 62,598 shares (Direct)

Footnotes (1)

1. Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of April 1, 2027, April 1, 2028 and April 1, 2029, subject to the reporting person's continuous service through each such vesting date. The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 1, 2027, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Strem Brian M.

(Last) (First) (Middle)

C/O KIORA PHARMACEUTICALS, INC.

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS CA 92024

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		A		16,733(1)	A	$0	62,598	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.98	03/06/2026		A		33,467		04/01/2027(2)	04/01/2036	Common Stock	33,467	$0	33,467	D

Explanation of Responses:

1. Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of April 1, 2027, April 1, 2028 and April 1, 2029, subject to the reporting person's continuous service through each such vesting date.

2. The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 1, 2027, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.

Remarks:

	/s/ Melissa Tosca, Attorney-in-Fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Kiora (KPRX) CEO Brian Strem receive?

Brian Strem received two equity awards: an option to purchase 33,467 shares of Kiora Common Stock at $1.98 per share and a grant of 16,733 restricted Common shares, both issued as compensation rather than open-market purchases.

How do Brian Strem’s new stock options at Kiora (KPRX) vest?

The option to buy 33,467 Kiora shares becomes exercisable as to one-third of the underlying shares on April 1, 2027. The remaining balance vests in equal monthly installments on the first day of each month over the following two years, contingent on continued service.

What is the vesting schedule for Brian Strem’s restricted Kiora (KPRX) stock?

The 16,733 restricted shares of Kiora Common Stock vest in three equal installments. One-third of the shares vest on each of April 1, 2027, April 1, 2028, and April 1, 2029, provided Brian Strem remains in continuous service through each vesting date.

What is the exercise price and expiration date of Brian Strem’s Kiora options?

The newly granted stock option has an exercise price of $1.98 per Kiora Common share and an expiration date of April 1, 2036. This gives Brian Strem a long-dated right to purchase shares once they vest, if it is economically attractive.

How many Kiora (KPRX) shares does Brian Strem hold after these grants?

After the restricted stock grant, Brian Strem directly holds 62,598 shares of Kiora Common Stock. This total reflects his position following the reported award of 16,733 restricted shares, according to the ownership figure disclosed in the Form 4 filing.

Were Brian Strem’s Kiora (KPRX) equity transactions open-market buys or compensation grants?

The transactions were compensation-related grants, not open-market trades. Both the stock option and restricted stock were awarded under Kiora’s 2024 Equity Incentive Plan at a reported price of $0.00 per share, consistent with typical executive incentive awards.